home > news > 2008 > april > astrazeneca publish results of study using simcyp simulator
AstraZeneca publish results of study using Simcyp Simulator
Date: 07 Apr 2008
Researchers at AstraZeneca have published the results of a recent drug-drug interaction investigation undertaken by Dermot McGinnity et al. The aims of the study were to analyse the contribution of individual CYPs towards total clearances of classic CYP2D6 substrates, and to assess approaches for the in vivo prediction of CYP-mediated drug-drug interactions (DDIs) from in vitro data.
The Simcyp Population-based ADME Simulator was used as a prediction tool in the research as it incorporates a physiologically-based method that simulates the changes in inhibitor and substrate concentrations over time, the generation of inhibitory metabolites, the inhibition of gastrointestinal metabolism, active uptake of the inhibitor into the liver and the impact of population variability.
In their discussion of the results, the authors conclude that the Simcyp platform is “...a useful simulation tool for use within drug discovery, development and in the rationale and design of clinical DDI studies.”
The paper is entitled, ‘Integrated in vitro analysis for the in vivo prediction of cytochrome P450 mediated drug-drug interactions’. The article appears as an e-publication ahead of print in the journal Drug Metabolism and Disposition.
Please click here for a link to the abstract and full text options.